Nucleotides and Alzheimer’s disease: the latest study

In 2019 Prosol announced the promising result of a first study on the role of dietary nucleotides (Ribodiet®) in Alzheimer disease. Last July a scientific study on the same topic was published on Biomedicine and Pharmacotherapy review; the study showed extremely interesting benefits of RIBODIET® in alleviating memory decline, neuroinflammation and oxidative stress.

Alzheimer’s disease is one of the most common form of dementia, characterized by the deposition of extracellular amyloid-β (Aβ) peptides in the brain. The neuronal death, that characterizes this neurodegenerative disorder, causes irreversible cognitive impairment and behavioral alteration.

The option of natural-derived products and nutraceuticals is scientifically solid and to be considered for a future medical option in industrialized countries. Natural products are not an alternative to drugs but, on the contrary, can be helpful to complement the pharmacological therapy and prevent the onset of chronic diseases.

In this context, has been showed that Ribonucleotides are able to improve the clinical outcomes in immunosuppressive and inflammatory-based diseases.


Scientific investigations on Ribonucleotides for Alzheimer’s disease

A recent study[1] evaluated the effects of a ribonucleotides-based ingredient (Ribodiet®) in a non-genetic mouse model of AD. Given the strict involvement of nucleosides and nucleotides on neuronal and cognitive functions, the team of the study[2] decided to examine whether a ribonucleotides-based ingredient could ameliorate Aβ‐induced neuro-inflammation and oxidative stress.

Results of the study

The study presented the first and complete overview of how the supplementation with a ribonucleotide-based ingredient (Ribodiet®) may have a positive impact on synaptic degeneration in Alzheimer Disease and in controlling the most common form of neurodegenerative disease. In particular the study showed that:

  • Ribodiet® lessens oxidative stress and brain inflammation
  • Ribodiet® modulates amyloid pathology in a murine model of Alzheimer disease
  • Ribonucleotide-based ingredients are effective on neuro-inflammatory-based disease/s

These results lay the first pillar for a rationale use of ribonucleotide-based ingredients for the treatment of Alzheimer disease and other age-related diseases. The study was published on Biomedicine & Pharmacotherapy.  You can view and download full text PDF.


To learn more about Ribodiet please click here or contact Prosol Spa:
Via Carso, 99 – 24040 MADONE (BG), Italy.
Tel +39

[1] Original article – Supplementation with ribonucleotide-based ingredient (Ribodiet®) lessens oxidative stress, brain inflammation, and amyloid pathology in a murine model of Alzheimer on Biomedicine & Pharmacotherapy, Volume 139, July 2021, 111579
[2] Anella Saviano, GianMarco Casillo, Federica Rauccia, Alessia Pernice, Cristina Santarcangelo, Marialuisa Piccolo, MariaGrazia Ferraro, Miriam Ciccone, Alessandro Sgherbini, Nadia Pedretti, Daniele Bonvicini, Carlo Irace, Maria Daglia, Nicola Mascolo, Francesco Maione.